Alexion Recalls Certain Lots of Intravenous Drug Soliris

US drugmaker Alexion Pharmaceuticals said it is voluntarily recalling certain lots of Soliris, an intravenous drug for two potentially fatal blood disorders that can damage the kidneys, heart and brain.

The company said the recall was related to its earlier manufacturing process, which had prompted a similar recall in November.

Alexion initiated the recall due to the presence of visible particles found in a single lot of Soliris during a test, it said in a statement.

The company said it did not expect the recall to have any financial impact or interrupt supply of the drug.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read